Wills Eye Glaucoma Clinical Trials

Glaucoma: A 90-Day, Open-label, multi-site, pilot study evaluating the safety and intraocular lowering effect of delivering Travoprost using a punctal plug delivery system (Evolute®) in subjects with elevated intraocular pressure.

PI: Reza Razeghinejad, MD

In an open-label study, we are evaluating replacing the use of a daily instilled ocular hypotensive drop with a punctal plug delivery system to deliver an eye pressure-lowering drug to the eye for 28 days.

Patients with a history of open-angle glaucoma or ocular hypertension (high eye pressure without glaucoma damage) who meet all study inclusion/exclusion criteria will be asked to discontinue their current hypotensive medication for six weeks. At the end of six weeks, if a subject still meets all study inclusion/exclusion criteria, a drug-releasing punctal plug will be inserted into each eye.

The study will involve a total of five visits (baseline, week 6, the day after, day 7 and day 28 after being inserted with a punctal plug). Subjects will be compensated for their participation in the study.

Clinical Study Coordinator: Jeanne Molineaux, jmolineaux@willseye.org


Glaucoma: Acute Changes in Optic Nerve Head (ONH) and Macular Blood Flow after Caffeine Consumption in Glaucoma Patients and Healthy Subjects: A Quantitative Optical Coherence Tomography Angiography (OCTA) Study.

Brief Summary:
Caffeine is the most widely consumed drinking nutrient in the world. Caffeine effects various organs and the vascular system. It may decrease ocular blood flow due to vasoconstriction.

Detailed Description:
Ingestion of caffeine in glaucoma patients and healthy subjects may decrease peripapillary and macular blood flow in the back of the eye.

The primary objective of this study is to assess the acute changes in peripapillary and macular blood flow before and after an intake of oral caffeine (200 milligram tablet) in glaucoma patients and healthy subjects by using optical coherence tomography angiography (OCTA) scans. This novel imaging tool creates three-dimensional angiograms to assess signal changes caused by flowing blood cells in a non-invasive angiogram scan that does not touch the eye. Blood flow is shown as vessel density measured in percentage. IOP will be assessed for effects of caffeine as well.

To learn more about this study, please contact Clinical Study Coordinator: Jeanne Molineaux, COA at 215-825-4713.


Glaucoma: Study in Patients with Glaucoma or Ocular Hypertension.

Wills Eye Study Doctor: Jonathan S. Myers, MD

Glaucoma or ocular hypertension is a condition in which the intraocular pressure (a measurement of the fluid pressure inside your eye) is higher than normal.

The purpose of this clinical trial is to determine how safely and effectively NCX470 eye drops lower high intraocular pressure in adult patients with ocular hypertension (high eye pressure) or open-angle glaucoma. Patients who qualify for treatment will receive either NCX470 eye drops or latanoprost eye drops and dose both eyes once daily in the evening for 3 months. The duration of this study is up to 5 months with a total of 6 visits. With the exception of the first visit (Screening Visit), intraocular pressure is checked at 8AM, 10AM, and 4PM. The Screening Visit should last about 2 to 4 hours. All other visits may last 3 to 4 hours if you choose to step out of the study site between pressure checks, or 8 to 9 hours if you remain at the study site during the full visit. Qualifying patients will receive study-related medical evaluations and study medication at no cost and will be compensated for their time in the study.

To learn more about the study, please contact Sheryl S. Wizov, COA at 215-928-3221.


SANTEN ANGEL-2: A Phase IIb, Randomized, Double-Masked, Active-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared with Timolol Maleate Ophthalmic Solution 0.5% in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension

PI: Jonathan Myers, MD

Description: click here.

To learn more about this study, please contact Clinical Coordinator: Meskerem Divers, mdivers@willseye.org